Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 688 results
Found 688 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Mugavero MJ, Pence BWells, Whetten K, et al. "Predictors of AIDS-related morbidity and mortality in a southern U.S. Cohort." AIDS Patient Care STDS. 2007;21(9):681-90.
Crump JA, Wu X, Kendall MA, et al. "Predictors and outcomes of Mycobacterium tuberculosis bacteremia among patients with HIV and tuberculosis co-infection enrolled in the ACTG A5221 STRIDE study." BMC Infect. Dis.. 2015;15:12.
Eron JJ, Park J-G, Haubrich R, et al. "Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy." Antimicrob. Agents Chemother.. 2009;53(6):2335-41.
Rutstein SE, Hosseinipour MC, Weinberger M, et al. "Predicting resistance as indicator for need to switch from first-line antiretroviral therapy among patients with elevated viral loads: development of a risk score algorithm." BMC Infect. Dis.. 2016;16(1):280.
Balagopal A, Asmuth DM, Yang W-T, et al. "Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study." J. Acquir. Immune Defic. Syndr.. 2015;70(2):163-71.
Shivakoti R, Gupte N, Yang W-T, et al. "Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy." Nutrients. 2014;6(11):5061-78.
Schackman BR, Scott CA, Sax PE, et al. "Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial." Clin. Infect. Dis.. 2007;45(8):1062-70.
Abbas UL, Anderson RM, Mellors JW. "Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings." J. Acquir. Immune Defic. Syndr.. 2006;41(5):632-41.
Sha BE, Tierney C, Cohn SE, et al. "Postpartum viral load rebound in HIV-1-infected women treated with highly active antiretroviral therapy: AIDS Clinical Trials Group Protocol A5150." HIV Clin Trials. 2011;12(1):9-23.
Hennig S, Svensson EM, Niebecker R, et al. "Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs." J. Antimicrob. Chemother.. 2016;71(5):1330-40.
Makita-Chingombe F, Kutscher HL, DiTursi SL, Morse GD, Maponga CC. "Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations." J Drug Deliv. 2016;2016:3810175.
Jiang W, Lederman MM, Hunt P, et al. "Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection." J. Infect. Dis.. 2009;199(8):1177-85.
Kuritzkes DR, Ribaudo HJ, Squires KE, et al. "Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s." J. Infect. Dis.. 2007;195(8):1169-76.
Sinxadi PZuleika, McIlleron HMargaret, Dave JAlex, et al. "Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations." Medicine (Baltimore). 2016;95(2):e2385.
Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.
Schifitto G, Yiannoutsos CT, Simpson DM, et al. "A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy." J. Neurovirol.. 2006;12(4):328-31.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Tungsiripat M, Kitch D, Glesby MJ, et al. "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206." AIDS. 2010;24(11):1781-4.
Marks KM, Kitch D, Chung RT, et al. "Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239." J. Acquir. Immune Defic. Syndr.. 2014;65(3):345-9.
Henry K, Katzenstein D, Cherng DWeng, et al. "A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102." J. Acquir. Immune Defic. Syndr.. 2006;42(2):140-8.
Smith DM, Mathews WChristophe. "Physicians' attitudes toward homosexuality and HIV: survey of a California Medical Society- revisited (PATHH-II)." J Homosex. 2007;52(3-4):1-9.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Derache A, Wallis CL, Vardhanabhuti S, Bartlett J, Kumarasamy N, Katzenstein D. "Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection." J. Infect. Dis.. 2016;213(2):250-6.
Verma SS, Frase AT, Verma A, et al. "PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG)." Pac Symp Biocomput. 2016;21:57-68.
Moore CB, Verma A, Pendergrass S, et al. "Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols." Open Forum Infect Dis. 2015;2(1):ofu113.
Para MF, Schouten J, Rosenkranz SL, et al. "Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200." J. Acquir. Immune Defic. Syndr.. 2010;53(4):491-5.
Dooley KE, Luetkemeyer AF, Park J-G, et al. "Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin." Antimicrob. Agents Chemother.. 2014;58(9):5245-52.
Sherman KE, Kang M, Sterling R, et al. "Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection." World J Hepatol. 2017;9(4):217-223.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Gulick RM, Su Z, Flexner C, et al. "Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211." J. Infect. Dis.. 2007;196(2):304-12.